arrow
S

Simona Soverini

Institute of Hematology Seragnoli
H指数:62
被引数:1.5万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Nilotinib versus imatinib with early switch from imatinib to nilotinib to obtain treatment-free remission in newly diagnosed chronic myeloid leukemia patients: the analysis of the first co-primary endpoint

尼洛替尼与伊马替尼治疗新诊断慢性髓性白血病患者的比较,包括早期从伊马替尼转换为尼洛替尼以实现治疗缓解的首次主要终点分析

Leukemia
IF13.4
2025-11-180
OAAI
2025 European LeukemiaNet recommendations for the management of chronic myeloid leukemia

2025欧洲白血病网关于慢性粒细胞白血病治疗的建议

Leukemia
IF13.4
2025-07-110
OA
SETD2 loss of function is a recurrent event in advanced-phase chronic myeloid leukemia and contributes to genomic instability

SETD2功能缺失是进展期慢性髓性白血病中的常见事件,并导致基因组不稳定。

2025-04-240
OAAI
ASXLI Mutations at Diagnosis Did Not Impact on the Depth of Molecular Response (MR) and on Treatment-Free Remission (TFR) Eligibility in Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Patients (pts) Receiving either Nilotinib (NIL) First-Line or Imatinib (IM) with Early Switch to NIL in Case of No Optimal Response in the SUSTRENIM Clinical Trial

ASXLI突变在诊断时并未影响慢性期(CP)慢性粒细胞白血病(CML)患者(pts)在SUSTRENIM临床试验中接受尼洛替尼(NIL)一线治疗或伊马替尼(IM)联合早期切换至尼洛替尼(NIL)(在无最佳应答情况下)的分子应答深度(MR)及无治疗缓解(TFR)资格。

BLOOD
IF23.1
2024-11-051
PRE
Comparison between indolent systemic mastocytosis and clonal mast cell disease not meeting WHO diagnostic criteria: A nationwide multicenter retrospective analysis
2024-04-290
PRE
Treatment-free remission in chronic myeloid leukemia patients treated front-line with nilotinib: 10-year follow- up of the GIMEMA CML 0307 study
2022-04-0714
OAAI
INCB84344-201: Ponatinib and steroids in frontline therapy for unfit patients with Ph+ acute lymphoblastic leukemia
2022-03-1544
OAAI
Case Report: A Novel Activating FLT3 Mutation in Acute Myeloid Leukemia

病例报告: 急性髓系白血病中一种新的激活型FLT3突变

2021-09-305
OAAI
Inotuzumab ozogamicin and donor lymphocyte infusion is a safe and promising combination in relapsed acute lymphoblastic leukemia after allogeneic stem cell transplant

在异基因干细胞移植后复发的急性淋巴细胞白血病中,Inotuzumab ozogamicin和供体淋巴细胞输注是一种安全且有希望的组合

2021-05-0712
PRE
Pharmacological Inhibition of WIP1 Sensitizes Acute Myeloid Leukemia Cells to the MDM2 Inhibitor Nutlin-3a

WIP1的药理抑制使急性髓性白血病细胞对MDM2抑制剂Nutlin-3a敏感

2021-04-0610
OAAI